Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha-beta T cells - CD19 HD allogeneic CAR T
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD19 HD Allo CAR T is an allogeneic CAR-T cell therapy being developed by Editas Medicine in collaboration with Bristol Myers Squibb. The therapy consists of allogeneic alpha-beta (αβ) T cells engineered using CRISPR-based gene editing technology to target CD19, a protein expressed on the surface of B cells. Designed as an off-the-shelf treatment, it aims to treat various autoimmune diseases by depleting pathogenic B cells. This program represents Editas Medicine's first in-house developed technology for clinical use in the allogeneic CAR-T setting, and its IND/CTA has been accepted for Phase 1 clinical trials.
- Other names
- alpha-beta T cells - CD19 HD allogeneic CAR TCD19 HD allogeneic CAR TCD-19 HD allogeneic CAR TCD 19 HD allogeneic CAR T
02
Targets
Beyond the preview
Go deeper on alpha-beta T cells - CD19 HD allogeneic CAR T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpha-beta T cells - CD19 HD allogeneic CAR T.